ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Would Fund 152 More Grants Under President’s Budget

February 17, 1995

Fredrickson, Upton Kill Plan To Convert FCRC To NIH Satellite, Will Continue L-B Contract

February 9, 1979

AACR President Kripke Calls For Dedicated Translational Research

March 11, 1994

Cooperative Groups Cut In On $1 Million Head 7 Neck Projects

March 25, 1977

DCCP Board Okays Noncompetitive Procurements

June 11, 1982

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

December 26, 2014